← Search & browse all drugs
ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Other antivirals
labuvirtide
J05AX33
Forms & Strengths
- 10 mg/mL solution for injection
Adult Dosing
- Initial dose: 300 mg subcutaneously at week 0, 4, and 12, then 300 mg every 4 weeks
- Missed dose: administer as soon as possible, then continue with regular schedule
Pediatric Dosing
- Not established for patients under 18 years
Indications
- In combination with other antiretroviral agents for the treatment of HIV-1 infection
Mechanism of Action
- HIV-1 capsid inhibitor, preventing viral capsid assembly and replication
Contraindications
- Hypersensitivity to labuvirtide or any component of the formulation
Adverse Reactions
- Most common: injection site reactions, headache, fatigue, musculoskeletal pain
- Serious: immune reconstitution syndrome, potential for HIV-1 resistance with monotherapy
Drug Interactions
- Not significantly metabolized by CYP450 enzymes, no major interactions expected with other antiretroviral agents
- Potential interaction with rifamycin antibiotics, monitor for reduced labuvirtide efficacy
Curated Content: Needs Vetting Before Put to Clinical Use